<DOC>
	<DOC>NCT00476034</DOC>
	<brief_summary>This 39-week, active controlled, study is designed to assess long-term efficacy, safety and tolerability of lumiracoxib 100mg od in patients with osteoarthritis (OA) of the knee who participated in the 13-week core CCOX189A2361 study.</brief_summary>
	<brief_title>Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Lumiracoxib</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>Any patient who completed the core study 2361 may enter the extension trial upon signing informed consent. A patient is defined as completing if he/she completed the core study 2361 up to and including Visit 6 (week 13) without a major protocol violation. Those patients for whom continued treatment in the extension study is not considered appropriate by the treating physician Those patients who were noncompliant or who demonstrated a major protocol violation in the core study. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>lumiracoxib</keyword>
	<keyword>celecoxib</keyword>
	<keyword>Cox-2</keyword>
	<keyword>knee</keyword>
</DOC>